Citius Oncology reports 120% jump in LYMPHIR wholesaler sales
Citius Oncology (CTOR) reported a 120% increase in LYMPHIR wholesaler sales, with 792 units sold in Q4 2026, up from 360 in Q3. Institutional orders also rose, and the company aims for 100 priority institutions by year-end. Data is preliminary and unaudited. LYMPHIR is an FDA-approved immunotherapy for cutaneous T-cell lymphoma. CTOR is a subsidiary of Citius Pharmaceuticals (CTXR).
How this was made
The 30-second read
Why it matters
The company’s preliminary Q4 wholesaler unit sales and institution ordering metrics indicate accelerating commercial adoption, but traders should wait for audited financials and gross-to-net reconciliation in the December 10-K.
Market read
Fresh preliminary commercial volume data can shift expectations for LYMPHIR revenue trajectory into the December reporting window.
What to watch
Institution count rose (54 vs 44) and prescribing centers ordered slightly more vials, but gross-to-net adjustments and order timing could materially change reported revenue versus unit sales.
Background
Citius Oncology launched LYMPHIR in the US in December 2025 and is working toward formulary placement at 100 priority institutions by year-end.
Ticker impact
Citius Oncology reported preliminary LYMPHIR wholesaler unit sales rising to 792 in Q4 from 360 in the prior quarter ended June 30.
Likely upward bias as traders price better near-term revenue visibility from stronger wholesaler orders and institution coverage.
The article provides fresh, company-specific commercial volume data (units and institutions) but labels it preliminary and unaudited, limiting certainty until the full 10-K.
Market effects
Signals improving uptake for an FDA-approved targeted immunotherapy, which can influence sentiment toward small-cap oncology commercial execution.
Primarily US commercial coverage and wholesaler ordering dynamics.
Limited direct global impact since the article focuses on US wholesaler sales and nationwide coverage.
Counterpoint
Because revenue is recognized on fulfillment of wholesaler orders and the figures are preliminary and unaudited, the jump may not translate proportionally into audited revenue or sustained demand.
Key entities
- companyCitius Oncology Inc.
NASDAQ-listed company reporting preliminary LYMPHIR wholesaler unit sales and institution ordering metrics for fiscal Q4 ended Sept. 30, 2026.
- productLYMPHIR
FDA-approved targeted immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma.
- companyCitius Pharmaceuticals Inc.
Majority-owned parent of Citius Oncology, referenced as CTXR.
